Intra-arterial Cereport (RMP-7) and Carboplatin: A Dose Escalation Study for Recurrent Malignant Gliomas

Intra-arterial Cereport (RMP-7) and Carboplatin: A Dose Escalation Study for Recurrent Malignant... AbstractOBJECTIVE:Animal and human studies have shown increased delivery of radiolabeled compounds across the blood-brain-tumor barrier using intra-arterial (IA) Cereport (RMP-7; Alkermes Inc., Cambridge, MA) with a radiolabeled tracer. This present study assesses the safety, tolerance, and preliminary efficacy of the IA administration of carboplatin with Cereport.METHODS:An open-label dose escalation study of IA Cereport (10-300 ng/kg) with 100 mg of IA carboplatin was conducted in 11 patients with recurrent malignant gliomas and 1 patient treated adjuvantly after radiation therapy. Tumor size and laboratory and clinical statuses were assessed.RESULTS:Adverse events were mainly neurological in nature and corresponded to the anatomic location of the tumor. Karnofsky performance scale scores did not decline, overall, for those patients who had tumor response. Tumor shrinkage was observed in three of six evaluable patients who received a dose of 300 ng/kg with durable responses of 60, 64, and 106+ weeks.CONCLUSION:Adverse events were mainly neurological in nature and corresponded to the anatomic location of the tumor. Karnofsky performance scale scores did not decline, overall, for those patients who had tumor response. Tumor shrinkage was observed in three of six evaluable patients who received a dose of 300 ng/kg with durable responses of 60, 64, and 106+ weeks. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurosurgery Oxford University Press

Intra-arterial Cereport (RMP-7) and Carboplatin: A Dose Escalation Study for Recurrent Malignant Gliomas

Intra-arterial Cereport (RMP-7) and Carboplatin: A Dose Escalation Study for Recurrent Malignant Gliomas

Intra-arterial Cereport (RMP-7) and Carboplatin: A Dose Escalation Study for Recurrent Malignant Gliomas Timothy F. Cloughesy, M .D ., Keith L. Black, M .D ., Y. Pierre Gobin, M .D ., Keyvan Farahani, Ph.D., Gillian Nelson, P.A., Pablo Villablanca, M .D ., Fairooz Kabbinavar, M .D ., Fernando Vineula, M .D ., Cornelius FH. Wortel, M .D ., Ph.D. Departments of Neurology (TFC, G N ), Surgery (KLB), Radiology (Y P G , KF, PV, FV), and M edicine (FK) and the )onsson Comprehensive C an cer Center (TFC , K LB , FK), University of California, Los Angeles School of M edicine, Los Angeles, California, and Alkermes Inc. (C H W ), Cambridge, Massachusetts O B JE C T IV E : Animal and human studies have shown increased delivery of radiolabeled compounds across the blood-brain-tumor barrier using intra-arterial (IA) Cereport (RMP-7; Alkermes Inc., Cam bridge, MA) with a radiolabeled tracer. This present study assesses the safety, tolerance, and prelim inary efficacy of the IA admin­ istration of carboplatin with Cereport. M E T H O D S : An open-label dose escalation study of IA Cereport (1 0 -3 0 0 ng/kg) with 100 mg of IA carboplatin was conducted in 11 patients with recurrent malignant gliomas and 1 patient treated adjuvantly after radiation therapy. Tumor size and laboratory and clinical statuses were assessed. RESULTS: Adverse events were mainly neurological in nature and corresponded to the anatomic location of the tum or. Karnofsky perform ance scale sco res did not d e clin e , o v e ra ll, for those patients w ho had tumor response. Tumor shrinkage was observed in three of six evaluable patients who received a dose of 300 ng/kg with durable responses of 60, 64, and 1 06 + weeks. C O N C L U S IO N : Previous studies have demonstrated increased permeability in human gliomas using IA Cereport. This study demonstrates durable imaging responses using 1 00 mg of IA carboplatin in combination with Cereport. The drug combination in this patient population seems to be...
Loading next page...
 
/lp/ou_press/intra-arterial-cereport-rmp-7-and-carboplatin-a-dose-escalation-study-urgG3aHUcC
Publisher
Congress of Neurological Surgeons
Copyright
© Published by Oxford University Press.
ISSN
0148-396X
eISSN
1524-4040
D.O.I.
10.1097/00006123-199902000-00015
Publisher site
See Article on Publisher Site

Abstract

AbstractOBJECTIVE:Animal and human studies have shown increased delivery of radiolabeled compounds across the blood-brain-tumor barrier using intra-arterial (IA) Cereport (RMP-7; Alkermes Inc., Cambridge, MA) with a radiolabeled tracer. This present study assesses the safety, tolerance, and preliminary efficacy of the IA administration of carboplatin with Cereport.METHODS:An open-label dose escalation study of IA Cereport (10-300 ng/kg) with 100 mg of IA carboplatin was conducted in 11 patients with recurrent malignant gliomas and 1 patient treated adjuvantly after radiation therapy. Tumor size and laboratory and clinical statuses were assessed.RESULTS:Adverse events were mainly neurological in nature and corresponded to the anatomic location of the tumor. Karnofsky performance scale scores did not decline, overall, for those patients who had tumor response. Tumor shrinkage was observed in three of six evaluable patients who received a dose of 300 ng/kg with durable responses of 60, 64, and 106+ weeks.CONCLUSION:Adverse events were mainly neurological in nature and corresponded to the anatomic location of the tumor. Karnofsky performance scale scores did not decline, overall, for those patients who had tumor response. Tumor shrinkage was observed in three of six evaluable patients who received a dose of 300 ng/kg with durable responses of 60, 64, and 106+ weeks.

Journal

NeurosurgeryOxford University Press

Published: Feb 1, 1999

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial